Body and blood clearance and marrow radiation dose of 131I-lym-l in patients with b-cell malignancies

Gerald L Denardo, M. A. Mahe, S. J. Denardo, D. J. Macey, G. R. Mirick, W. D. Erwin, M. W. Groch

Research output: Contribution to journalArticle

42 Scopus citations

Abstract

Fifty-eight per cent of patients with B-cell malignancies had durable responses to treatment with 131I- Lym-1. Myelosuppression manifested by peripheral blood cytopenia was the radiation dose-limiting toxicity. The mean biologic half-times were 3.3 and 31.2 h for the fast and slow phases, respectively, of the blood clearance and 33.5 h for the clearance from the total body. Nonpenetrating radiation from the blood contributed 0.18 rad and penetrating radiations from the total body contributed 0.18 rad per administered mC-1 to the bone marrow. The average total contribution from both of these sources was 0.36 + 0.14 rad mCi-1. Clearances and marrow radiation doses were remarkably constant among different patients and among different therapy doses for the same patient. These results are potentially useful as an initial approximation for other mouse monoclonal antibodies of the same isotype. While radiation to normal marrow from ’spill-over' incident to specific targeting of 131I-Lym-l on malignant B- cells in the marrow is not addressed in this publication because it is unique for each patient, it should be considered in the case of individual patient.

Original languageEnglish (US)
Pages (from-to)587-595
Number of pages9
JournalNuclear Medicine Communications
Volume14
Issue number7
StatePublished - 1993

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Fingerprint Dive into the research topics of 'Body and blood clearance and marrow radiation dose of <sup>131</sup>I-lym-l in patients with b-cell malignancies'. Together they form a unique fingerprint.

  • Cite this

    Denardo, G. L., Mahe, M. A., Denardo, S. J., Macey, D. J., Mirick, G. R., Erwin, W. D., & Groch, M. W. (1993). Body and blood clearance and marrow radiation dose of 131I-lym-l in patients with b-cell malignancies. Nuclear Medicine Communications, 14(7), 587-595.